CHARM Therapeutics

CHARM Therapeutics is a pioneering biotechnology research company focused on revolutionizing the development of next-generation small molecule therapeutics. With a commitment to innovation and patient outcomes, CHARM Therapeutics employs cutting-edge protein-ligand intelligence to design and deliver novel treatments for critical illnesses.

CHARM Therapeutics' lead program targets acute myeloid leukemia (AML) with a next-generation menin inhibitor. This innovative approach is specifically engineered to overcome the limitations of first-generation inhibitors, maintaining potency against all known clinical resistance mutations and offering the potential for durable responses. Operating from its primary location in London, GB, and with a presence in Cambridge, GB, CHARM Therapeutics is dedicated to advancing healthcare through groundbreaking research and therapeutic solutions.

CHARM Therapeutics is poised for significant growth and impact in the biotechnology sector. As CHARM Therapeutics continues to expand its research and development efforts, it remains committed to transforming the landscape of small molecule therapeutics. We invite the management team at CHARM Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further enhance its visibility and commercial development.